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BACKGROUND: Several recent studies have shown that screen detection remains an independent prognostic factor after adjusting for
disease stage at presentation. This study compares the molecular characteristics of screen-detected with symptomatic breast cancers
to identify if differences in tumour biology may explain some of the survival benefit conferred by screen detection.
METHODS: A total of 1379 women (aged 50–70 years) with invasive breast cancer from a large population-based case–control study
were included in the analysis. Individual patient data included tumour size, grade, lymph node status, adjuvant therapy, mammographic
screening status and mortality. Immunohistochemistry was performed on tumour samples using 11 primary antibodies to define five
molecular subtypes. The effect of screen detection compared with symptomatic diagnosis on survival was estimated after adjustment
for grade, nodal status, Nottingham Prognostic Index (NPI) and the molecular markers.
RESULTS: Fifty-six per cent of the survival benefit associated with screen-detected breast cancer was accounted for by a shift in the NPI,
a further 3–10% was explained by the biological variables and more than 30% of the effect remained unexplained.
CONCLUSION: Currently known biomarkers remain limited in their ability to explain the heterogeneity of breast cancer fully. A more
complete understanding of the biological profile of breast tumours will be necessary to assess the true impact of tumour biology on
the improvement in survival seen with screen detection.
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Breast cancer is the most common female cancer in the UK with
more than 45000 women diagnosed per annum. The National
Health Service Breast Screening Programme (NHSBSP) was
introduced in 1988 in the UK and around 15000 breast cancer
cases are now detected every year through screening. The NHSBSP
initially offered three yearly mammography to women aged 50–65
years, however, since 2004 the upper age limit has been increased
to 70 years, with approximately two million women now screened
in the UK each year.
The widespread introduction of mammographic screening for
breast cancer has led to a significant reduction in breast cancer
mortality. The policy of offering screening is associated with a 20%
reduction in breast cancer mortality and the effect of actually
attending screening is likely to be considerably larger (Vainio,
2002). Although women with screen-detected breast cancers have
an improved prognosis compared with those diagnosed with
tumours outside of screening (i.e. symptomatic tumours), there are
multiple biases that may contribute to this difference. These
include lead-time bias (cancers detected by screening are identified
earlier in their natural history) and length bias (cancers with a
favourable natural history are more likely to be detected by
screening as they remain asymptomatic for longer; Shapiro et al,
1974; Zahl et al, 2004).
Screen-detected cancers are more likely to be smaller in size and
well differentiated, and are less likely to be associated with regional
lymph node involvement (Porter et al, 1999; Weaver et al, 2006).
Until recently, the survival benefit conferred from screen detection
has largely been attributed to this stage shift. However, several
recent studies have shown that screen detection remains an
independent prognostic factor after adjusting for disease stage
(Joensuu et al, 2004; Shen et al, 2005; Wishart et al, 2008). In the
largest UK series, which was performed by our group, only 72% of
the survival benefit associated with screen-detected breast cancers
was accounted for by age and shift in the Nottingham Prognostic
Index (NPI), a prognostic tool based on tumour size, grade
and lymph node status (Wishart et al, 2008). These results confirm
that lead-time bias alone cannot fully explain the improved
prognosis associated with screening. The remaining survival
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sbenefit conferred from screen-detection has not been fully
explained, but may relate to differences in tumour biology between
screen-detected and symptomatic cancers.
In recent years, microarray-based technology has resulted in the
identification of clinically relevant molecular subtypes of breast
cancer, providing insights into the molecular heterogeneity of the
disease (Perou et al, 2000; Sorlie et al, 2003). Five distinct breast
cancer subtypes have been identified based on gene expression
signatures: luminal A, luminal B, HER2 overexpressing, basal-like
and normal breast tissue-like. The differences in gene expression
patterns among the subtypes reflect basic alterations in the cell
biology of the tumours and have been associated with significant
variation in clinical outcome. Luminal A tumours have been
associated with the best prognosis whereas basal-like and HER2-
overexpressing tumours show shorter disease-free intervals and
worse overall survival (Sorlie et al, 2003).
Protein expression profiling using immunohistochemistry has
been used to describe a similar molecular taxonomy of the disease
(Callagy et al, 2003; Abd El-Rehim et al, 2005; Jacquemier et al,
2005). Luminal A and luminal B breast cancers express the
oestrogen receptor (ER) and are also frequently progesterone
receptor (PR) positive. HER2 expression is associated with the
HER2-overexpressing and luminal B subtypes. Basal-like cancers
are characteristically negative for ER, PR and HER2 expression
(i.e. triple negative) but may express basal cytokeratins (CK5-6 and
CK14) and the epidermal growth factor receptor (EGFR) (Nielsen
et al, 2004; Rakha et al, 2006). In this context, immunohistochem-
istry can be used to identify distinct molecular subtypes of breast
cancer, contributing to our understanding of the biological
diversity of the disease.
It is currently not known whether variation in the molecular
characteristics of screen-detected vs symptomatic breast cancers
contributes to the differences seen in prognosis between these
two groups. The aims of the present study were to examine the
molecular characteristics of screen-detected vs symptomatic breast
cancers and to identify if differences in tumour biology may
explain some of the survival benefit conferred by screen detection.
MATERIALS AND METHODS
Study population
A total of 1379 women diagnosed with invasive breast cancer were
included in this analysis from their participation in a large
population-based case–control study; the Study of Epidemiology
and Risk Factors in Cancer Heredity (SEARCH). Cases for
SEARCH are identified through the Eastern Cancer Registration
and Information Centre and details of the study have been
published previously (Lesueur et al, 2005). The criteria for inclu-
sion of cases in the current analysis were those aged between 50
and 70 years at diagnosis (the age range of the NHSBSP) with
available tumour samples, pathology data (tumour size, tumour
grade, lymph node status) and individual outcome data (vital
status at last follow-up and date of death). The NPI was calculated
for each case using tumour size, lymph node status and
histological grade, and cases were classified into five different
prognostic groups based on the NPI; excellent (NPIo2.4),
good (2.4oNPIo3.4), moderate 1 (3.4oNPIo4.4), moderate 2
(4.4oNPIo5.4) and poor (NPIX5.4) (Sundquist et al, 1999).
Tumour samples and immunostaining
Tissue microarrays were constructed using a tissue microarrayer
(Beecher Instruments, Sun Prairie, WI, USA) as previously
described with a single representative 0.6mm tissue core taken
from each tumour block (Kononen et al, 1998). Sections from the
tissue microarrays were cut at 3mm for subsequent immuno-
staining. Immunostaining using the BOND-maX automated immu-
nostainer (Leica Microsystems, Bucks, UK) was performed for the
following 11 primary antibodies: ER, PR, HER2, CK 5-6, CK14, EGFR,
E-cadherin, Ki-67, BCL2, p63 and a-smooth muscle actin (ASMA).
Details of the primary antibodies and antigen retrieval methods are
given in Supplementary Table 1. Tumours and tissues with known
staining patterns were used as positive immunostaining controls and
normal tissues were used a negative controls.
Following antibody staining, the slides were scanned into the
Ariol high-throughput image analysis system (Applied Imaging
Corp, San Diego, CA, USA). All immunohistochemistry was scored
by SJD. Details of the scoring methods used and the cut-off values
applied to each marker to indicate positive and negative staining
are shown in Supplementary Table 1. Cores containing no evidence
of tumour or carcinoma in situ were excluded from the analysis.
Nuclear staining for ER and PR was recorded using the Allred
scoring system; a simple additive scoring system of an intensity
and proportion value that gives a range from 0 to 8 (intensity score
range 0–3; proportion score range 0–5 (0¼no staining; 1p1%;
2¼1–10%; 3¼11–33%; 4¼34–66%; 5¼67–100%)). A total
score of 42 was defined as positive (Leake et al, 2000). HER2 was
scored using the HercepTest; score 0¼no staining or staining in
p10% cells, 1¼weak incomplete membrane staining in 410% of
cells, 2¼moderate complete membrane staining in 410% cells,
3¼strong complete uniform membranous staining in 410% of
cells. A score of 2 or 3 was considered positive (Carlson et al,
2006). Scoring methods and cut-off values for the other
immunohistochemical markers were defined from previous studies
(Callagy et al, 2003, 2006; Rakha et al, 2006, 2007).
Molecular subtype classification
Tumours were classified into five molecular groups based on the
expression of ER, PR, HER2, basal cytokeratins and EGFR as
follows: subtype 1 (luminal A)¼ERþ and/or PRþ and HER2 ;
subtype 2 (luminal B)¼ERþ and/or PRþ and HER2þ; subtype
3 (HER2 over-expressing)¼ER  and PR  and HER2þ; subtype 4
(triple negative without expression of core basal markers)¼ER ,
PR ,H E R 2   and CK5/6 ,C K 1 4  ,E G F R  ; subtype 5 (triple nega-
tive with expression of core basal markers)¼ER ,P R  , HER2 
and CK5/6þ and/or CK14þ and/or EGFRþ.
Statistical analysis
Differences between screen-detected and symptomatic patients
regarding categorical variables were assessed using the w
2-test. Cox
regression analysis was used to determine the effect of each factor
on all-cause mortality after diagnosis. Follow-up was censored on
the date of death from any cause, or, if death did not occur, on the
date last known alive or at 15 years after diagnosis, whichever
came first. Time at risk began on the date of entry into SEARCH to
allow for the fact that SEARCH is an ongoing epidemiology study
and some cases are recruited after diagnosis (Azzato et al, 2009).
The effect of screen detection as compared with symptomatic
diagnosis on survival was first estimated unadjusted and then
adjusted for NPI and individual marker expression. The percen-
tage of the effect of screen detection accounted for by other factors
was estimated using the measure mentioned by Freedman et al
(1992). This is defined as
P ¼ 100 1  
a
b
no
where b is the unadjusted logarithm of the hazard ratio and a the
adjusted. Thus, for example, if after adjustment there is no effect,
a¼0, and the Freedman statistic will be 100%. If the adjustment
makes no difference whatever, a¼b, and the Freedman statistic is
0%. All analyses were performed using SPSS statistical software
version 16.0, or Intercooled Stata version 9.0 (StataCorp, College
Station, TX, USA).
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Characteristics of breast cancers and mode of detection
Baseline clinical and pathology data from the 1379 women included
in the analysis are summarised in Table 1. Of these women, 610 (44%)
had screen-detected tumours and 769 (56%) had symptomatic
tumours detected without screening. Mean follow-up of the study
population was 7 years (range 0.7–16 years). Breast cancers
identified through screening were smaller than those found without
screening (85 vs 59% respectively had tumour size p2cm,
Po0.0001). Screen-detected tumours were more likely to have
lower histological grade (34 vs 23% were grade 1, Po0.0001) and
less likely to have lymph node involvement (25 vs 40%, Po0.0001).
In keeping with these findings, screen-detected tumours were more
likely to have favourable NPI categories (Po0.0001). Women with
screen-detected tumours were also less likely to receive adjuvant
systemic chemotherapy (17 vs 30%, Po0.0001).
A higher proportion of tumours detected at screening were
ERþ (86 vs 74%, Po0.0001)) and PRþ (74 vs 65%, P¼0.002)
(Table 2). BCL2 was highly expressed in screen-detected tumours
(90 vs 83%, P¼0.003) and lower rates of Ki-67 positivity (6 vs 15%,
Po0.0001) were identified. There was no significant difference in
the expression of the basal cytokeratins between the two groups
but a higher proportion of tumours detected without screening
expressed EGFR (6 vs 11%, P¼0.012).
Molecular subtypes of breast cancer and mode of detection
The distribution of the five defined molecular subtypes was
explored in cancers detected at screening and those detected
without screening (Table 2; Figure 1). Tumours detected at
Table 1 Case and tumour characteristics
Mode of breast cancer
detection
Characteristic
Screen
detected
(n¼610)
Not screen
detected
(n¼769) P-value
Age at diagnosis (years)
50–59 371 (61) 520 (68) 0.009
60–70 239 (39) 249 (32)
Mean follow-up (years, range) 6.9 (1.3–15.6) 7.1 (0.7–16) 0.06
Deaths, n (%) 52 (9) 153 (20) o0.0001
Tumour size, n (%)
2cm 482 (85) 429 (59) o0.0001
42–5cm 84 (14) 284 (39)
45cm 4 (1) 19 (2)
Grade, n (%)
1 181 (34) 153 (23) o0.0001
2 277 (51) 296 (45)
3 82 (15) 213 (32)
Nodal status, n (%)
Negative 400 (75) 426 (60) o0.0001
Positive 134 (25) 290 (40)
NPI group, n (%)
Excellent 101 (25) 57 (10) o0.0001
Good 132 (33) 112 (21)
Moderate 1 100 (25) 123 (23)
Moderate 2 46 (11) 147 (27)
Poor 25 (6) 106 (19)
Morphology, n (%)
Ductal 454 (74) 547 (71) 0.05
Lobular 102 (17) 159 (21)
Other 54 (9) 61 (8)
Chemotherapy, n (%)
Yes 83 (17) 204 (30) o0.0001
No 406 (83) 474 (70)
Hormonal therapy, n (%)
Yes 543 (89) 656 (85) 0.10
No 67 (11) 112 (15)
Abbreviation: NPI¼Nottingham Prognostic Index.
Table 2 Molecular characteristics
Mode of breast cancer detection
Characteristic
Screen
detected
(n¼610)
Not screen
detected
(n¼769) P-value
ER status, n (%)
Positive 352 (86) 410 (74) o0.0001
Negative 56 (14) 144 (26)
PR status, n (%)
Positive 302 (74) 350 (65) 0.002
Negative 106 (26) 191 (35)
HER2 status, n (%)
Positive 34 (8) 63 (12) 0.10
Negative 371 (92) 478 (88)
CK5-6 status, n (%)
Positive 44 (11) 52 (10) 0.65
Negative 371 (89) 483 (90)
CK14 status, n (%)
Positive 16 (4) 20 (4) 0.83
Negative 392 (96) 528 (96)
EGFR status, n (%)
Positive 25 (6) 60 (11) 0.012
Negative 367 (94) 477 (89)
E-cadherin status, n (%)
Positive 303 (74) 415 (75) 0.65
Negative 107 (26) 137 (25)
Ki-67 status, n (%)
Positive 26 (6) 86 (15) o0.0001
Negative 382 (94) 473 (85)
BCL2 status, n (%)
Positive 360 (90) 442 (83) 0.003
Negative 42 (10) 93 (17)
p63 status, n (%)
Positive 3 (1) 2 (1) 0.43
Negative 403 (99) 543 (99)
ASMA status, n (%)
Positive 18 (4) 26 (5) 0.75
Negative 390 (96) 510 (95)
Subtype 1, n (%)
a 322 (85) 366 (72) o0.0001
Subtype 2, n (%) 21 (5) 32 (6) 0.62
Subtype 3, n (%) 12 (3) 24 (5) 0.216
Subtype 4, n (%) 7 (2) 28 (6) 0.005
Subtype 5, n (%) 19 (5) 56 (11) 0.001
Abbreviations: ASMA¼a-smooth muscle actin; EGFR¼epidermal growth factor
receptor; ER¼oestrogen receptor; NPI¼Nottingham Prognostic Index; PR¼pro-
gesterone receptor.
aSubtypes: 1¼(ER+ and/or PR+) and HER2 ;2¼(ER+ and/or
PR+) and HER2+; 3¼(ER  and PR ) and HER2+; 4¼(ER ,P R  , HER2 ) and
(CK5/6 , CK14  and EGFR ); 5¼(ER ,P R  , HER2 ) and (CK5/6+ and/or
CK14+ and/or EGFR+).
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sscreening were more likely to belong to the luminal A subtype
(subtype 1; 85 vs 72%, Po0.0001). Furthermore, screen-detected
tumours were less likely to belong to the basal-like subtype as
defined by either the triple negative phenotype (subtype 4; 2 vs 6%,
P¼0.005) or the triple negative phenotype and the expression of
core basal markers (subtype 5; 5 vs 11%, P¼0.001)). The pre-
valence of luminal B (7 vs 5%, P¼0.62) and HER2-overexpressing
subtypes (5 vs 3%, P¼0.22) was similar between the screen-
detected and non-screen-detected groups.
Overall survival by mode of detection and molecular
subtype
Univariate analysis Women with screen-detected tumours had
improved overall survival compared to women with tumours
detected without screening (Po0.0001; Figure 2). Univariate
analysis of mode of detection, age at diagnosis, tumour size,
grade, nodal status and NPI group showed that all factors except
age had highly significant effects on survival (Table 3).
When comparing survival according to molecular subtype, the
luminal A subtype was associated with the best overall survival
and the HER2-overexpressing subtype with the worst (Table 4).
Tumours detected by screening generally had more favourable
outcomes than non-screen-detected cancers regardless of the
molecular subtype (Table 3). In the luminal A subtype (subtype 1),
overall survival at 15 years was 94% among women with screen-
detected cancers compared to 84% in the non-screen-detected
group (P¼0.001).
Multivariate analysis The effect of screen detection on survival
was then explored in a multivariate analysis after adjustment for
tumour characteristics, the NPI, individual molecular biomarker
expression and molecular subtype (Table 5). The effect of screen
detection on survival was significantly attenuated after adjustment
for the NPI with the hazard ratio changing from 0.43 to 0.69.
Further adjustment of the model to incorporate expression of
individual markers or the molecular subtype resulted in minimal
change in the survival benefit conferred by screen detection.
The Freedman estimate of the proportion of the survival
advantage from screen detection attributable to NPI was 56%. As
one might argue that histological grade, a component of the NPI, is
a biological variable, we also estimated the proportion attributable
Screen detected Not screen detected
5%
5%
6%
6%
11%
5%
85%
72%
Subtype 1
Subtype 2
Subtype 3
Subtype 4
Subtype 5
Subtype 1
Subtype 2
Subtype 3
Subtype 4
Subtype 5
2%
3%
Figure 1 Breast cancer molecular subtypes by mode of breast cancer detection. Subtypes: 1¼(ERþ and/or PRþ) and HER2 ;2 ¼(ERþ and/or
PRþ) and HER2þ;3¼(ER  and PR ) and HER2þ;4¼(ER ,P R  , HER2 ) and (CK5/6 , CK14  and EGFR ); 5¼ (ER ,P R  , HER2 ) and (CK5/
6þ and/or CK14þ and/or EGFRþ).
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Figure 2 Overall survival by mode of breast cancer detection.
Table 3 Univariate analysis of overall survival
Hazard ratio (95% CI) P-value
Mode of detection (n¼1379)
Not screen detected 1.00
Screen detected 0.43 (0.31–0.59) o0.0001
Age at diagnosis (n¼1400)
50–59 1.00
60–70 1.01 (0.74–1.35) 0.99
Tumour size (n¼1319)
2cm 1.00
42–5cm 2.11 (1.56–2.85) o0.0001
45cm 5.88 (3.23–10.73) o0.0001
Grade (n¼1218)
1 1.00
2 1.98 (1.21–3.23) 0.006
3 5.42 (3.35–8.75) o0.0001
Nodal status (n¼1267)
Negative 1.00
Positive (1–3 nodes) 2.35 (1.65–3.35) o0.0001
Positive (4 nodes) 8.18 (5.75–11.65) o0.0001
NPI group (n¼961)
Excellent 1.00
Good 3.22 (1.10–9.47) 0.034
Moderate 1 4.70 (1.64–13.52) 0.004
Moderate 2 7.36 (2.61–20.77) o0.0001
Poor 27.77 (10.09–76.41) o0.0001
Abbreviation: NPI¼Nottingham Prognostic Index.
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sto size and node status only. This was 53%. Adjustment for the
other molecular characteristics in addition to NPI gave attributable
proportions ranging from 59 to 66%. Multivariate adjustment for
several biological variables did not substantially change the
proportion of the screen detection effect explained. Thus,
additional adjustment for molecular characteristics explained a
further 3–10% of the survival advantage of screen-detected
tumours in addition to NPI (6–13% in addition to size and node
status). Currently known biomarkers and tumour characteristics
still remain limited in their ability to explain the heterogeneity of
breast cancer fully. It is likely that a more complete understanding
of the biological profile of breast tumours will be necessary to
eliminate potential length bias and adjust for its impact on the
improvement in survival seen with screen detection.
DISCUSSION
Women with screen-detected cancers have a strong survival
advantage compared to women with symptomatic cancers detected
without screening (Gotzsche and Nielsen, 2006). The majority of
this survival benefit is explained by stage shift as tumours detected
by screening are identified earlier in their natural history and
consequently have an improved prognosis (Wishart et al, 2008).
However, after adjustment for age and NPI, approximately one-
third of the screen detection survival advantage has remained
unexplained. It has been hypothesised that the remaining survival
benefit conferred by screen detection may relate to differences in
tumour biology between screen-detected and symptomatic can-
cers. We analysed the molecular characteristics of screen-detected
vs symptomatic breast cancers in 1379 women diagnosed with
invasive breast cancer in the East of England to identify if
differences in tumour biology may explain some of the survival
benefit conferred by screen detection. Although differences in the
molecular subtype of screen-detected vs symptomatic cancers were
identified, the expression of individual molecular biomarkers had
minimal effect on the improved outcome associated with screen
detection.
Favourable molecular characteristics have previously been
described in screen-detected tumours including higher expression
of ER and PR and less frequent expression of HER2 and Ki-67
(Crosier et al, 1999; Joensuu et al, 2004). Our current analysis
confirmed these findings and identified that screen-detected
tumours were more likely to be ERþ,P Rþ and Ki-67 . In our
study, a low frequency of HER2þ breast cancer was identified,
which is not an unexpected finding given that the cohort was
population based. The proportion of HER2þ cases was found to
be similar between the screen-detected and symptomatic tumours.
Our analysis also identified that a higher proportion of breast
cancers diagnosed without screening were triple negative. Sympto-
matic tumours were more likely to be EGFRþ although expression
of the basal cytokeratins (CK5-6 and CK14) did not differ
significantly between the screen-detected and symptomatic
tumours. A previous small study of 95 interval cancers diagnosed
in Norway has reported that cancers detected without screening
were more likely to show a basal epithelial phenotype as defined by
CK5-6 positivity (Collett et al, 2005). Finally, we identified that
screen-detected tumours were more likely to show higher
expression of BCL2, an anti-apoptotic protein whose expression
is associated with improved survival from breast cancer (Callagy
et al, 2006, 2008).
Despite the identification of distinct differences in the molecular
characteristics of screen-detected vs symptomatic breast cancers,
our analysis showed minimal attenuation of the screen-detected
survival advantage after adjustment for the expression of
individual molecular biomarkers or molecular subtype in multi-
variate analysis. The Freedman estimates of the proportion of the
effect suggest that the NPI explains 56% of the effect, up to a
further 10% is explained by the biological variables and more than
30% of the effect remains unexplained. In a recent study by Shito
et al (2008), cancer detection at screening independently predicted
favourable distant disease-free survival when molecular subtype
was included as a covariate in multivariate analysis in addition to
age, grade and tumour size. The authors concluded that the
differences in molecular subtypes of screen-detected vs sympto-
matic breast cancers accounted in part for the better outcome of
screen-detected cancers, however, the effect of molecular subtype
on the survival advantage conferred by screen detection was not
assessed in this analysis.
The policy of offering mammographic screening has led to a
reduction in breast cancer mortality of around 20% (Vainio, 2002).
The population mortality benefit occurs as a result of the much
higher survival observed in screen-detected cancers. Around two-
thirds of this survival benefit can be accounted for by age and shift
in the NPI. The residual survival advantage from screen detection,
although small, currently remains unexplained. Despite obvious
differences in the molecular characteristics of screen-detected vs
symptomatic tumours, our analysis indicates that these differences
in tumour biology only account for a small proportion of the
residual survival benefit. Measurement of tumour attributes is not
Table 4 Overall survival by breast cancer molecular subtype
Overall survival (15 years)
Molecular
subtype n
Screen
detected (%)
Not screen
detected (%) P-value
Subtype 1
a 688 94 84 0.001
Subtype 2 53 86 78 0.52
Subtype 3 36 83 54 0.12
Subtype 4 35 86 64 0.24
Subtype 5 75 84 79 0.60
aSubtypes: 1¼(ER+ and/or PR+) and HER2 ;2¼(ER+ and/or PR+) and HER2+;
3¼(ER  and PR ) and HER2+; 4¼(ER ,P R  , HER2 ) and (CK5/6 , CK14 
and EGFR ); 5¼(ER ,P R  , HER2 ) and (CK5/6+ and/or CK14+ and/or EGFR+).
Table 5 Attenuation of the effect of screen detection on survival after
adjustment for different factors
Factors
adjusted for
Hazard Ratio
(95% CI)
Screen detected vs not
screen detected P-value
Freedman
statistic (%)
None 0.43 (0.31–0.59) o0.0001 —
Grade 0.50 (0.35–0.71) o0.0001 18
Size 0.52 (0.37–0.74) o0.0001 22
Nodal status 0.60 (0.43–0.84) 0.003 39
Size and nodal status 0.67 (0.47–0.94) 0.02 53
NPI 0.69 (0.46–1.03) 0.07 56
NPI and ER 0.71 (0.45–1.14) 0.16 59
NPI and PR 0.72 (0.45–1.16) 0.18 61
NPI and HER2 0.72 (0.45–1.15) 0.16 61
NPI and CK5-6 0.75 (0.47–1.19) 0.22 66
NPI and CK14 0.68 (0.43–1.09) 0.11 54
NPI and EGFR 0.63 (0.38–1.03) 0.07 45
NPI and E-cadherin 0.65 (0.41–1.05) 0.08 49
NPI and Ki-67 0.72 (0.45–1.14) 0.08 61
NPI and BCL2 0.71 (0.44–1.15) 0.16 59
NPI and p63 0.59 (0.36–0.94) 0.03 37
NPI and ASMA 0.72 (0.45–1.14) 0.16 61
NPI and molecular
subtype
0.64 (0.38–1.08) 0.09 47
Abbreviations: ASMA¼a-smooth muscle actin; EGFR¼epidermal growth factor
receptor; ER¼oestrogen receptor; NPI¼Nottingham Prognostic Index; PR¼pro-
gesterone receptor.
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which might be better explained by stage and other histological
tumour characteristics if these were measured more precisely. In
addition, there are prognostic factors that were unavailable to us,
such as lymphovascular invasion. Adjustment for these might
further explain some of the better survival of screen-detected cases.
However, currently known biomarkers and tumour characteristics
still remain limited in their ability to explain the heterogeneity of
breast cancer fully. It is likely that a more complete understanding
of the biological profile of breast tumours will be necessary to
eliminate potential length bias and adjust for its impact on the
improvement in survival seen with screen detection.
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